Robert Alan Nagourney

1.2k total citations
39 papers, 937 citations indexed

About

Robert Alan Nagourney is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Robert Alan Nagourney has authored 39 papers receiving a total of 937 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Cancer Research. Recurrent topics in Robert Alan Nagourney's work include Cancer Treatment and Pharmacology (10 papers), Cancer Genomics and Diagnostics (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). Robert Alan Nagourney is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Cancer Genomics and Diagnostics (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). Robert Alan Nagourney collaborates with scholars based in United States, Brazil and Germany. Robert Alan Nagourney's co-authors include Steven S. Evans, Timothy Cardozo, Brittany B. Carson, Anthony M.C. Brown, Laura A. Ekas, Ramanuj DasGupta, Steve Evans, Foster C. Gonsalves, Cheryl A. Brewer and John S. Link and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Robert Alan Nagourney

37 papers receiving 898 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Alan Nagourney United States 17 432 312 144 144 129 39 937
Verena Materna Germany 20 552 1.3× 632 2.0× 96 0.7× 155 1.1× 220 1.7× 33 1.1k
Yuji Yaginuma Japan 19 646 1.5× 424 1.4× 90 0.6× 117 0.8× 208 1.6× 51 1.2k
Larry M. Weisenthal United States 16 462 1.1× 413 1.3× 104 0.7× 79 0.5× 151 1.2× 33 1.1k
Gary L. Goldberg United States 17 416 1.0× 303 1.0× 51 0.4× 183 1.3× 108 0.8× 33 867
Soon-Cen Huang Taiwan 13 372 0.9× 141 0.5× 49 0.3× 79 0.5× 154 1.2× 19 730
H. Meden Germany 19 355 0.8× 492 1.6× 75 0.5× 288 2.0× 146 1.1× 68 1.0k
Huifang Huang China 16 627 1.5× 290 0.9× 53 0.4× 55 0.4× 201 1.6× 80 1.1k
Katarzyna Marta Lisowska Poland 16 736 1.7× 295 0.9× 73 0.5× 280 1.9× 338 2.6× 36 1.3k
Timothy Childs Canada 14 457 1.1× 262 0.8× 41 0.3× 224 1.6× 168 1.3× 21 930
Wenwen Guo China 19 544 1.3× 263 0.8× 64 0.4× 87 0.6× 275 2.1× 80 1.1k

Countries citing papers authored by Robert Alan Nagourney

Since Specialization
Citations

This map shows the geographic impact of Robert Alan Nagourney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Alan Nagourney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Alan Nagourney more than expected).

Fields of papers citing papers by Robert Alan Nagourney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Alan Nagourney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Alan Nagourney. The network helps show where Robert Alan Nagourney may publish in the future.

Co-authorship network of co-authors of Robert Alan Nagourney

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Alan Nagourney. A scholar is included among the top collaborators of Robert Alan Nagourney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Alan Nagourney. Robert Alan Nagourney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Evans, Steven S., et al.. (2023). Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants. Genes. 14(3). 747–747. 5 indexed citations
3.
Evans, Steven S., et al.. (2022). Drugging the undruggable-targeting P53: A comparative analysis of APR-246 and coti-2 in human tumor primary culture explants.. Journal of Clinical Oncology. 40(16_suppl). e15092–e15092. 1 indexed citations
4.
Tewari, Krishnansu S., Robert E. Bristow, Fabio Cappuccini, et al.. (2021). Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis. Gynecologic Oncology. 163(1). 162–170. 9 indexed citations
5.
6.
Nagourney, Robert Alan, et al.. (2020). Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin. European Journal of Surgical Oncology. 47(4). 738–742. 42 indexed citations
7.
Usón, Pedro Luiz Serrano, et al.. (2019). Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy. SHILAP Revista de lepidopterología. 7. 2050313X19838739–2050313X19838739. 1 indexed citations
8.
Evans, Steven S., et al.. (2012). Optimal combination therapy for advanced colorectal cancer: An examination of synergy and antagonism with EGFR inhibition.. Journal of Clinical Oncology. 30(15_suppl). e14075–e14075. 2 indexed citations
9.
Nagourney, Robert Alan, et al.. (2012). Functional profiling to select chemotherapy in untreated, advanced or metastatic non-small cell lung cancer.. PubMed. 32(10). 4453–60. 15 indexed citations
10.
Nagourney, Robert Alan, et al.. (2007). Clinical Responses to EGFr-TKI’s characterized by drug-induced cell death in human NSCLC primary cultures. Journal of Clinical Oncology. 25(18_suppl). 18184–18184. 1 indexed citations
11.
Brewer, Cheryl A., John A. Blessing, Robert Alan Nagourney, Mark A. Morgan, & Parviz Hanjani. (2006). Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A Phase II Study of the Gynecologic Oncology Group. Gynecologic Oncology. 103(2). 446–450. 48 indexed citations
12.
Nagourney, Robert Alan, et al.. (2004). Carboplatin & gemcitabine repeating doublet in recurrent breast cancer. Journal of Clinical Oncology. 22(14_suppl). 851–851. 4 indexed citations
13.
Nagourney, Robert Alan, et al.. (2003). Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. British Journal of Cancer. 89(9). 1789–1795. 22 indexed citations
14.
Nagourney, Robert Alan, Cheryl A. Brewer, Stephen E. Radecki, et al.. (2002). Phase II Trial of Gemcitabine plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Ovarian Cancer Patients. Gynecologic Oncology. 88(1). 35–39. 73 indexed citations
15.
Chun, Helen H., Sergi Castellvı́-Bel, Zhijun Wang, et al.. (2002). TCL‐1, MTCP‐1 and TML‐1 gene expression profile in non‐leukemic clonal proliferations associated with ataxia‐telangiectasia. International Journal of Cancer. 97(6). 726–731. 15 indexed citations
16.
Nagourney, Robert Alan. (2001). Gemcitabine plus cisplatin in breast cancer.. PubMed. 15(2 Suppl 3). 28–33. 23 indexed citations
17.
Nagourney, Robert Alan, et al.. (2000). Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients. Journal of Clinical Oncology. 18(11). 2245–2249. 95 indexed citations
18.
Nagourney, Robert Alan. (1998). Oral Limonene: Combined Prenylation Inhibitor Therapy of Cancer. Journal of Medicinal Food. 1(2). 83–88. 4 indexed citations
19.
Nagourney, Robert Alan. (1998). Garlic: Medicinal Food or Nutritious Medicine?. Journal of Medicinal Food. 1(1). 13–28. 23 indexed citations
20.
Weisenthal, Larry M., et al.. (1987). Perturbation of in vitro drug resistance in human lymphatic neoplasms by combinations of putative inhibitors of protein kinase C.. PubMed. 71(12). 1239–43. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Verena Materna Breakdown of academic impact, for papers by Yuji Yaginuma Breakdown of academic impact, for papers by Larry M. Weisenthal Breakdown of academic impact, for papers by Gary L. Goldberg Breakdown of academic impact, for papers by Soon-Cen Huang Breakdown of academic impact, for papers by H. Meden Breakdown of academic impact, for papers by Huifang Huang Breakdown of academic impact, for papers by Katarzyna Marta Lisowska Breakdown of academic impact, for papers by Timothy Childs Breakdown of academic impact, for papers by Wenwen Guo
Rankless by CCL
2026